In 2022, the Yale Biotech Club launched two externship programs with Allyx Therapeutics and Cellinfinity Bio. The YBC externship programs aim to provide students with short-term, fast-paced opportunities to gain valuable hands-on experience in different careers.

 

​

​

​

​

​

​

​

​

​

​

​

​

​

 

Allyx Therapeutics is a clinical-stage start-up company spun out of Professor Strittmatter’s laboratory at Yale. The goal is to develop disease-modifying therapies for neurodegenerative diseases by treating the underlying cause of synapse loss and dysfunction. Through workshops, literature reviews, and cross-team collaboration, students learned how Allyx can expand into other neurodegenerative indications and build research programs beyond Alzheimer’s disease. 

​

​

​

​

​

​

Cellinfinity Bio is revolutionizing cell therapy by developing proprietary, next-generation technologies. The company pipeline consists of clinically engineered T cells, NK cells and other immune cells that have potent activity against multiple malignancies including solid tumors. Through this externship, students learned about company operations and strategy,  bioinformatics, and IP landscape analysis.